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Edited by Varda RotterAbstract In this study, we found that pectenotoxin-2 (PTX-2)
decreased cell viability and inhibited telomerase activity with
downregulation of hTERT expression in human leukemia cells.
PTX-2 treatment also reduced c-Myc and Sp1 gene expression
and DNA binding activity. Further chromatin immunoprecipita-
tion assay demonstrated that PTX-2 attenuated the binding of c-
Myc and Sp1 to the regulatory regions of hTERT. We also ob-
served that PTX-2 treatment attenuated the phosphorylation of
Akt, thereby reducing the phosphorylation and nuclear translo-
cation of hTERT. We concluded that PTX-2 suppressed telome-
rase activity through the transcriptional and post-translational
suppression of hTERT and this process precedes cellular diﬀer-
entiation of human leukemia cells.
Structured summary:
MINT-6742762:
hTERT (uniprotkb:O14746) physically interacts (MI:0218)
with AKT (uniprotkb:P31749) by anti bait coimmunoprecipita-
tion (MI:0006)
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Telomeres are responsible for maintaining chromosomal sta-
bility by preventing attrition as well as end-to-end fusions and
chromosomal rearrangements [1–3]. Actually, most normal
human somatic cells progressively lose their telomeres with
each cell division [4,5]; however, telomerase activity is reacti-
vated through an unknown mechanism in over 85% of human
cancer cells and spontaneously immortalized cells, allowingAbbreviations: PTX-2, pectenotoxin-2; TRAP, telomeric repeat ampli-
ﬁcation protocol; ELISA, enzyme-linked immunosorbent assay; ChIP,
Chromatin immunoprecipitation; PARP, DNA repair enzyme poly-
(ADP-ribose) polymerase
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doi:10.1016/j.febslet.2008.08.030these cells to survive with sustained telomeres [6,7]. Therefore,
this enzyme oﬀers an attractive target for chemoprevention
and other anticancer strategies.
The telomerase complex consists of two essential compo-
nents: hTERT [8,9] and hTR [10]. Although hTR is ubiqui-
tously expressed in most cells [10], expression of hTERT is
limited in germinal and cancer cells [6,7]. As a result, many
studies have focused on relationships between apoptosis and
telomerase activity using anticancer agents, in order to ﬁnd
the precise mechanism of hTERT expression, which is thought
to be a more attractive target than hTR [11,12]. The hTERT
promoter region includes two typical E-boxes and several
GC-boxes for transcription factors c-Myc and Sp1, respec-
tively [13]. c-Myc directly binds with E-box and induces
hTERT transcription and subsequent cell proliferation [14].
The core promoter for hTERT expression also contains Sp1
binding sites. Particularly, Sp1 works in conjunction with c-
Myc to activate transcription of hTERT [15]. In addition,
the regulation of hTERT activity is controlled in post-transla-
tional alterations [16–18], as well as at the transcriptional level.
Pectenotoxins are a group of natural toxins that can be ex-
tracted from marine sponges, also found in shellﬁsh and intox-
icated humans [19]. The most toxic compound in this group is
pectenotoxin-2 (PTX-2), which is isolated from Dinophysis
spp. [20,21]. Previous studies have been also shown that
PTX-2 may modify actin cytoskeletons due to its depolymer-
ization through their binding sites with actin in vitro and
in vivo [22,23]. In addition, this compound was reported to dis-
play selective and potent cytotoxicity against human lung, co-
lon, and breast cancer cells [24,25].
This study was designed to investigate the underlying mech-
anisms involved in the induction of apoptosis by PTX-2 in hu-
man leukemia cells, with special emphasis on its role on the
regulation of telomerase, an important molecular marker for
carcinogenesis.2. Materials and methods
2.1. Reagents and antibodies
PTX-2 was prepared as described previously [24]. Antibodies against
c-Myc, Sp1, DNA repair enzyme poly-(ADP-ribose) polymerase
(PARP), caspase-3, hTERT, and nucleolin were purchased from Santaation of European Biochemical Societies.
3264 M.-O. Kim et al. / FEBS Letters 582 (2008) 3263–3269Cruz Biotechnology (Santa Cruz, CA), and antibodies against a-tubu-
lin, phospho (p)-Akt, Akt, and Akt substrate were purchased from Cell
Signaling (Beverly, MA).
2.2. Cell culture
Human leukemia U937, THP-1, HL-60 cells, human prostate cancer
cell PC-3, and human colorectal cancer cell HCT116 were obtained
from the American Type Culture Collection (Manassas, VA). Cells
were maintained in an RPMI-1640 medium supplemented with 10%
heat-inactivated FBS and 1% penicillin–streptomycin (Sigma) in 5%
CO2 at 37C.
2.3. Flow cytometric analysis
In order to analyze the percentage of apoptotic cells with annexin V
staining, cells were washed in phosphate-buﬀered saline and then incu-
bated with annexin V-ﬂuorescein isothiocyanate (R&D Systems; Min-
neapolis, MN). Normal murine splenocytes were pooled, washed with
PBS, ﬁxed in 70% ethanol for 20 min at 20 C, and incubated with
40 lg/ml propidium iodide (PI; Sigma) and 100 lg/ml RNase A for
30 min at 37 C in the dark. In a parallel experiment, GFP-conjugated
CD11b antibody (Pharmingen; Sin Diego, CA) was used for the detec-
tion of cell diﬀerentiation. Cells were analyzed using a FACSCalibur
ﬂow cytometer (Becton Dickenson; San Jose, CA).2.4. In vitro caspase-3 activity assay
The activity of caspase-like protease was measured using a caspase
activation kit (R&D System) according to the manufacturers protocol.2.5. RNA extraction and RT-PCR
Total RNA was isolated using the Trizol reagent (GIBCO-BRL;
Gaithersburg, MD) according to the manufacturers recommenda-
tions. Genes of interest were ampliﬁed from cDNA which was reverse
transcribed from 1 lg of total RNA using the One-Step RT-PCR Pre-Fig. 1. PTX-2-induced apoptosis in human leukemia cells. Cells were seeded a
2 for 72 h. (A) Annexin V+ cells are represented on the x-axis, while the num
analyzed in normal murine splenocytes by ﬂow cytometry. Arrows indicate t
determined by the manufacturers protocol. (D) Western blot was performe
from three independent experiments. Statistical signiﬁcance was determinedmix (iNtRON Biotechnology; Sungnam, Republic of Korea). Primers
and conditions for the ampliﬁcation of hTERT, GAPDH, c-Myc, and
Sp1 have been described previously [26].
2.6. Western blot analysis
Total cell extracts were prepared using PRO-PREP protein extrac-
tion solution (iNtRON Biotechnology; Sungnam, Republic of Korea).
The preparation of cytoplasmic and nuclear extracts was conducted
using the NE-PER nuclear and cytosolic extraction reagents (Pierce;
Rockford, IL). Total cell extracts were separated on 10% polyacryl-
amide gels, and then transferred to nitrocellulose membranes using
standard procedures. The membranes were developed using an ECL
reagent (Amersham; Arlington Heights, IL).
2.7. Immunoprecipitation
The total cell extracts were immunoprecipitated with anti-hTERT
overnight at 4 C. Immune complexes were collected using protein
A/G-Sepharose beads (Santa Cruz Biotechnology), washed, and eluted
in sample buﬀer. Samples were run on 8% SDS–PAGE gels, trans-
ferred to nitrocellulose membranes, and probed with the Akt-substrate
antibody or hTERT antibody. Blots were developed using the ECL re-
agent.
2.8. Telomerase activity assay
Telomerase activity was measured using a TRAP-ELISA kit (Boeh-
ringer Mannheim; Mannheim, Germany) according to the manufac-
turers instructions.
2.9. Electrophoretic mobility shift assay (EMSA)
DNA–protein binding assays were carried out with nuclear extract.
Synthetic complementary c-Myc (5 0-GGA AGC AGA CCA CGT
GGT CTG CTT CC-3 0) and Sp1 (5 0-ATT CGA TCG GGG CGG
GGCGAG C-3 0) binding oligonucleotides (Santa Cruz) were 3 0-biotin-
ylated using the biotin 3 0-end DNA labeling kit (Pierce).t 4 · 104 cells/ml and treated with the indicated concentrations of PTX-
ber of cells counted is represented on the y-axis. (B) DNA content was
he population of cells in the sub-G1 phase. (C) Caspase-3 activity was
d by standard procedure. Data are expressed as overall means ± S.D.
by Students t-test (*P < 0.05 vs. vehicle control).
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The ChIP assay was performed using the EZ-Chip assay kit
according to the manufacturers protocol (Upstate Biotechnology;
Lake Placid, NY). The primers used for the ampliﬁcation of hTERT
promoter region were Sp1 (forward): 5 0-GGT ACC GAC CCC
CGG GTC CGC CCG GA-3 0 and Sp1 (reverse): 5 0-AAG CTT GCT
GCC TGA AAC TCG CGC CG-3 0 (284 bp DNA product); and c-
Myc (forward): 5 0-AGT GGA TTC GCG GGC ACA GA-30and c-
Myc (forward): 5 0-TTC CCA CGT GCG CAG CAG GA-30 (reverse)
(257 bp DNA product) [27,28].
2.11. Statistical analysis
Statistical analyses were conducted using SigmaPlot software (ver-
sion 6.0), and Scion Imaging software (http://www.scioncorp.com)
was used to quantify the results normalized to the control gene. Values
were presented as means ± S.D. Signiﬁcant diﬀerences between the
groups were determined using the unpaired Students t-test. Statistical
signiﬁcance was regarded at P < 0.05.3. Results
3.1. PTX-2 inhibits cell proliferation of leukemia cells
To determine the eﬀect of PTX-2 on cell growth, human
myeloid leukemia cells were treated with increasing concentra-
tions for 72 h, and apoptosis was analyzed using FACS ﬂow
cytometer. As shown in Fig. 1A, a 72 h exposure time of each
cell line to 10 ng/ml PTX-2 resulted in an increase of more than
50%, indicating an apoptotic population. However, normalFig. 2. Downregulation of telomerase activity by PTX-2. Leukemia cells
Telomerase activity was measured using a TRAP-ELISA kit (A) and TRAP
PCR was performed. (D) Western blot was performed by standard procedure.
3, and HCT116. Data are expressed as overall means ± S.D. from three indepe
t-test (*P < 0.05 vs. vehicle control).murine splenocytes cells had no eﬀect on cytotoxicity and cell
cycle distribution (Fig. 1B). In this process, PTX-2 exposure
also increased caspase-3 activity, which was observed to in-
crease over 3-fold as compared with control cells (Fig. 1C).
Western blot analysis revealed that 10 ng/ml of PTX-2 treat-
ment for 72 h resulted in the cleaved form of caspase-3
(Fig. 1D). The cleavage of PARP was consistently revealed
by the appearance of the 89 kDa cleaved intermediate in
PTX-2 treatment. Collectively, these data indicate that PTX-
2 inhibits cell viability and leads to caspase-3 activation in leu-
kemia cells.
3.2. PTX2 represses telomerase activity in leukemia cells
As shown in Fig. 2A, telomerase activity was signiﬁcantly re-
duced in cells after 72 h of exposure with PTX-2 in a dose-
dependent manner. To visualize the eﬀect observed by
TRAP-ELISA assay, we also investigated ladder formation
by telomerase activity. As expected, the addition of PTX-2
(10 ng/ml) decreased ladder formation by telomerase
(Fig. 2B). We next performed RT-PCR and Western blot anal-
ysis to examine changes in hTERT expression following treat-
ment with PTX-2. As indicated in Fig. 2C, hTERT mRNA
decreased in leukemia cells following PTX-2 treatment. Con-
cordantly, the level of hTERT protein was also shown to un-
dergo a decrease in the whole cell extraction fraction
(Fig. 2D). The PTX-2-induced downregulation in telomerasewere incubated with the indicated concentration of PTX-2 for 72 h.
assay (B). (C) Total RNA was isolated using a Trizol reagent and RT-
(E) Telomerase activity using TARP assay was assessed in HepG2, PC-
ndent experiments. Statistical signiﬁcance was determined by Students
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observed in another human cancer cell lines (Fig. 2E). These
results suggest that PTX-2 treatment induces the downregula-
tion of telomerase activity through suppression of hTERT
gene expression at the transcriptional levels.
3.3. PTX-2 downregulates c-Myc- and Sp1-dependent hTERT
gene expression in leukemia cells
We next examined whether PTX-2 treatment alters the
expression and DNA binding activity of c-Myc and Sp1 in leu-
kemia cells. As shown in Fig. 3A and B, the levels of c-Myc
mRNA and protein were markedly reduced in PTX-2-treated
cells. Sp1 was also downregulated in mRNA levels, but its pro-
teins were degraded at the same conditions. Additionally,Fig. 3. Downregulation of c-Myc and Sp1 by PTX-2. Cells were treated with
reagent and RT-PCR was performed. (B) Western blot was performed by
analyzed by a LightShiftTM chemiluminescent EMSA kit as described in Se
(left panel) and Sp1 (right panel). Total sonicated chromatin was used to use
against histone-H3 and rabbit IgG, respectively. I, input; N, negative control;
blotting using anti-c-Myc and anti-Sp1 antibodies in PC-3 and HCT116.PTX-2 treatment resulted in a signiﬁcant decrease of c-Myc
and Sp1 DNA binding activity in leukemia cells (Fig. 3C).
To further investigate the exact mechanism of PTX-2 on the
regulation of hTERT expression, ChIP assay was performed
to examine the binding of c-Myc and Sp1 on the hTERT pro-
moter regions. As shown in Fig. 3D, our results showed that
PTX-2 attenuated c-Myc (left panel) and Sp1 (right panel)
binding to the promoter regions of hTERT. PTX-2 was shown
to signiﬁcantly suppress the nuclear expression of c-Myc and
Sp1 in other two cancer cell lines tested, indicating that the ef-
fect of PTX-2 was not cell type speciﬁc (Fig. 3E). These results
indicate that PTX-2 attenuates hTERT gene expression
through suppression of c-Myc- and Sp1-binding on the regula-
tory regions of hTERT.10 ng/ml of PTX-2 for 72 h. (A) Total RNA was isolated using a Trizol
standard procedure. (C) c-Myc and Sp1 DNA binding activity was
ction 2. (D) ChIP assay was performed using antibodies against c-Myc
as input. Positive and negative controls were performed using antibody
and P: positive control. (E) Nuclear proteins were subjected to Western
Fig. 4. Suppression of Akt-dependent hTERT phosphorylation by PTX-2. Cells were incubated with the indicated concentrations of PTX-2 for 72 h.
(A) Western blot was performed by standard procedure. (B) The lysates were subjected to immunoprecipitation with the anti-hTERT antibody and
then blotted with anti-p-Akt substrate or anti-hTERT antibody. (C) Nuclear proteins were subjected to Western blotting using anti-hTERT
antibodies, and then normalized to nucleolin.
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dephosphorylation of Akt
Because Akt is reported to enhance human telomerase activ-
ity through the phosphorylation and nuclear translocation of
hTERT [17], we investigated whether PTX-2 treatment inacti-
vates the Akt pathway, resulting in hTERT dephosphorylation
and nuclear translocation. As shown in Fig. 4A, total leukemia
cell Akt levels did not change following treatment with 10 ng/
ml PTX-2 for 72 h, while p-Akt levels signiﬁcantly decreased.
Since the activation of Akt is known to directly phosphorylate
hTERT, which could subsequently translocate into the nu-
cleus, we also investigated whether phosphorylation and nucle-
ar translocation of hTERT was inhibited by PTX-2 treatment.
The cells were treated with PTX-2 and then used to prepare ly-
sates that were immunoprecipitated with the anti-hTERT anti-
body. The cell lysates were subjected to Western blotting with
the anti-p-Akt substrate antibody or anti-hTERT antibody. As
can be seen in Fig. 4B, PTX-2 decreased hTERT phosphoryla-
tion at a putative Akt phosphorylation site. As already high-
lighted, because phosphorylation of hTERT is necessary for
its nuclear translocation, we determined that PTX-2 also
blocked the nuclear translocation of hTERT (Fig. 4C). These
results suggest that PTX-2 decreases phosphorylation of
hTERT and thereby possibly inhibits its translocation to the
nucleus through the dephosphorylation of Akt.
3.5. PTX-2 induces cytodiﬀerentiation of leukemia cells
Expression of the CD11b antigen was analyzed at 72 h dur-
ing the suppression of telomerase activity by PTX-2 in leuke-Fig. 5. Diﬀerentiation of leukemia cells by PTX-2. To investigate cellular d
line) or absence (black-shaded line) of 10 ng/ml PTX-2. After 72-h incubation
within each histogram represents the incidence of CD11b+ cells. The resultsmia cells. Cells were stained with FITC-conjugated mouse
monoclonal antibody against human CD11b after 72 h of
PTX-2 treatment. As shown in Fig. 5, untreated cells were
grown in parallel and included as controls (black-shade line).
Following PTX-2 treatment, expression of CD11b signiﬁcantly
increased in three leukemia cells (white-shade line). These re-
sults indicate that telomerase transcription and activity may
be reduced in all these cell lines upon induction of diﬀerentia-
tion.4. Discussion
Telomerase is composed of a catalytic subunit, hTERT,
hTR, and TEP-1 [3–5]. In particular, hTERT has received con-
siderable attention for its role in regulating telomerase activity
[11,12]. The hTERT core promoter contains numerous tran-
scription factor binding sites, including two for c-Myc, ﬁve
for Sp1, one for Ets, and two for Inr [29,30]. Of all these tran-
scription factors, c-Myc binds directly to E-boxes at the pro-
moter of hTERT and activates hTERT transcription [14]. In
addition to the c-Myc recognition sequence (E-box), Sp1 is in-
volved in the regulation of hTERT promoter activity in vari-
ous human cells [13,15]. Similar to these ﬁndings, our results
indicate that PTX-2 suppresses telomerase activity in human
leukemia cells via the transcriptional downregulation of
hTERT through a reduction of c-Myc and Sp1 activity. Nev-
ertheless, we could not rule out the possibility that other tran-
scriptional factors might also be involved in the suppression ofiﬀerentiation, HL-60 cells were cultured in the presence (white-shaded
, cells were harvested and analyzed by ﬂow cytometry. The percentage
are representative of three independent experiments.
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implicated in the repression of telomerase activity [18]. It is
also known that telomerase inhibition precedes diﬀerentiation
of leukemia cells and may contribute to terminal diﬀerentia-
tion [31]. We found that ablation of telomerase may be compa-
nied with the diﬀerentiation of leukemia cells. Therefore,
further investigations are needed to identify inactivation mech-
anisms of telomerase and diﬀerentiation of leukemia cells by
PTX-2.
Akt is a potent inhibitor of apoptosis through a blocking of
caspase activation and the inhibition of chromatin condensa-
tion [32,33]. It has also been reported that constitutive and
inducible Akt activity promotes resistance to chemotherapy
in cancer cells [34]. Akt phosphorylation could also be a potent
inducer for telomerase activation via hTERT phosphorylation
linked to nuclear localization [17]. Nuclear translocation of
hTERT from a presumably nonfunctional cytosolic location
to a physiologically relevant nuclear compartment may be
one important mechanism involved in the regulation of telo-
merase function in cells. The loss of PTEN, which can act as
a counterpart of Akt, may allow malignant cells to inhibit tel-
omerase activity through decreasing hTERT mRNA levels
[35]. In this study, PTX-2 was observed to downregulate p-
Akt, and phosphorylation and translocation of hTERT. These
results clearly suggest that PTX-2 treatment regulates hTERT
at the post-translational level by downregulating its phosphor-
ylation by the Akt pathway. Recently, mitogen-activated pro-
tein kinases and serine/threonine kinases have also been shown
to phosphorylate hTERT and regulate telomerase activity
[36,37]. Therefore, further studies will be necessary to deter-
mine whether these kinases are related to the PTX-2–induced
downregulation of hTERT.
In conclusion, our study demonstrated that PTX-2 sup-
presses cell viability and telomerase activity in human leuke-
mia cells. Overall results suggest that PTX-2 can be used to
eﬀectively inhibit telomerase activity via the transcriptional
and post-translational suppression of hTERT.
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